Title: United States FDA drug approvals are persistent and polycyclic: Insights into economic cycles, innovation dynamics, and national policy

Author: Iraj Daizadeh, PhD, Takeda Pharmaceuticals, 40 Landsdowne St. Cambridge, MA, 02139, iraj.daizadeh@takeda.com

Abstract: It is challenging to elucidate the effects of changes in external influences (such as economic or policy) on the rate of US drug approvals. Here, a novel approach – termed the Chronological Hurst Exponent (CHE) – is proposed, which hypothesizes that changes in the long-range memory latent within the dynamics of time series data may be temporally associated with changes in such influences. Using the monthly number FDA's Center for Drug Evaluation and Research (CDER) approvals from 1939 to 2019 as the data source, it is demonstrated that the CHE has a distinct S-shaped structure demarcated by an 8-year (1939-1947) Stagnation Period, a 27-year (1947-1974) Emergent (time-varying Period, and a 45-year (1974-2019) Saturation Period. Further, dominant periodicities (resolved via wavelet analyses) are identified during the most recent 45-year CHE Saturation Period at 17, 8 and 4 years; thus, US drug approvals have been following a Juglar/Kuznet mid-term cycle with Kitchin-like bursts. As discussed, this work suggests that (1) changes in extrinsic factors (e.g., of economic and/or policy origin ) during the Emergent Period may have led to persistent growth in US drug approvals enjoyed since 1974, (2) the CHE may be a valued method to explore influences on time series data, and (3) innovation-related economic cycles exist (as viewed via the proxy metric of US drug approvals).

Keywords: FDA approvals, drug development, medical product, medicines, economic cycle, Schumpeter

## Introduction

Drug discovery and development (DDD) requires investment to maneuver a single putative medicine from discovery science to market approval for a given condition or disease. The investments cover the costs associated with acquiring both the hardware (e.g., laboratory materials and space) and software [explicit (e.g., patents) and tacit (e.g., know-how) knowledge] as well as executing the various DDD activities [1]. Ultimately, should an investigational candidate survive the attrition process and obtain marketing authorization (also known as marketing approval) by a health authority, a sponsor then enjoys economic rents secured from supplying the approval medicine. On the demand side, the patient receives a trusted medicine associated with a market innovation based on a new chemical and biologic entity, a cost advantage (generic), or a more efficient delivery of drug product [2].

Since the early 20<sup>th</sup> century to the present, in terms of drug development, the social, economic, and political environments have evolved dramatically. For example, the growth in the amount of governmental investment in research and development (R&D) [3], the number of R&D firms [4, 5], the volume of intellectual property (e.g., patents, trademarks, as well as peer-reviewed publications) [5, 6], the number of R&D policy initiatives (see Table 1 and discussion below), and the rise of the R&D cluster [7] have seemingly grown synchronistically and exponentially. As a case in point, in the US and across industries, Daizadeh [8,9] showed a statistical significant intercorrelation in the time course of R&D investment, the number of patent and trademark applications, peer-reviewed and media publications, and stock price of major indices in the US.

Importantly, the 20<sup>th</sup> century also gave rise to the modern regulated DDD industry including the invention of an objective, independent, and external agency (collectively termed the health authority (HA)). The HA performs a vital function by attesting to a medicine's quality, safety, and efficacy profile and to formally authorize a drug for marketing purposes in a given jurisdiction. Since its original

conception, there have been increasing refinement in its scope proportional to changes in the social environment through amendments in policy. For example, focusing on the US Food and Drug Administration (FDA), there has been an evolution in the number and variety of policy initiatives focused on providing oversight to the DDD process due exclusively to important social concerns regarding safety and efficacy of certain drugs circulating in inter-jurisdictional commerce [38]. The FDA policy environment has evolved considerably from placing under regulation on specific drugs (e.g., insulin and penicillin) and describing the basic tenets of the safety sciences in its infancy to building a robust infrastructure commencing in the 1960s with the Kefauver-Harris amendments to regular updates in the policy landscape starting in 1977, with the introduction of the Bioresearch Monitoring Program, pushing the frontiers of regulatory science into the 21<sup>th</sup> century (see Table 1; [38]).

Concomitantly, economic factors have also greatly influenced the landscape of DDD. Unlike the US (see 21 CFR 310 *et seq.*; 21 CFR 601 *et seq.*), in many jurisdictions (e.g., the European Union), HAs consider cost and/or reimbursement when assessing the merits of granting a marketing application. The ability of sponsors to obtain the economic rents from supplying quality, safe and efficacious HA-authorized drugs is a key driver that has sustained the DDD process. Among other factors, expected revenues from marketing an innovative HA-approved drug product would be proportional to monopolizing power of the intellectual property [1] as well as the amount of labor required to move the drug from concept to delivery, thereby requiring a broad assortment of various investments in terms of tangible and intangible assets. While beyond the scope of this work, cost estimates to secure marketing authorization vary based on the types of challenges experienced in various phases (e.g. target / modality in discovery; the number, length and type of clinical trials in development) [41], with significant savings expected with expediting development [42]. Thus, drug approvals may be thought of an economic outcome within a given jurisdiction, and should behave as such. One such test would be to investigate the presence of cycles in the number of approvals similar to that found in other forms of economic output.

Economic cycles, a wavelength between crests of development maxima over stagnation minima, are an active area of inquiry, not without controversy [10]. Juglar defined this periodicity over three phases: prosperity, crisis, and subsequent liquidation, and suggested an "approximate length of the cycle with crisis/liquidation taking 1-2 years, followed by a 6-7 year phase of prosperity [11; pp. 7]," with drivers to prosperity to crisis transition due to exuberance and thus over-speculation (ibid). Kitchin derived 'minor' and 'major' inventory cycles with wavelengths of 3.5 years (40 month) and "aggregates usually of two, and less seldom of three, minor cycles," respectively [12; pp. 10]. Subsequent to the introduction of these short and intermediate cycles, Kondratieff introduced the concept of the long-wave 50-60 year cycles [13]. Concomitantly, Kuznetz extrapolated 15-25 year cycles derived from data from "fluctuations in rates of population growth and immigrating but, also with investment delays in building, construction, transport infrastructure, etc... [14; pp. 2]." These authors extrapolated the information from a broad assortment of macro-economic data from US and Europe including climate, monetary, fiscal, consumption, among others.

Memory characteristics (also termed persistency) in the dynamics of typical econometrics captured over time are intimately connected with cycles and thus also to the underlying processes [15]. Technically, however, these same characteristics such as long-range memory processes are challenging to analyze and interpret due to (in part) self-similarity and typical non-stationary properties (as they confound spurious from true signals) [16]. The Hurst constant and wavelet analyses are statistical time series tools that may be calculated in such as a way as to avoid these challenges [17]. While there are other ways to define a Hurst constant, a measurement of memory, it is classically defined as  $H \sim ln(R / S)_t / ln(t)$ , where R and S is the rescaled range and standard deviation, respectively, and t is a time window. An H=0.5, an H<0.5, and an H>0.5 indicates a random walk, an anti-persistent, and a persistent (trend reinforcing) time series, respectively [18]. Wavelet analyses is a well-established group of time series methods that leverages the expansion and contraction of wave functions to resolve time series properties [19].

In this work, and the to the author's knowledge, this is the first investigation of the existence and evolution of persistency, and the existence of approval cycles (akin to economic cycles) within US drug approvals, which is treated as a macro-economic variable and a proxy metric for FDA policy. This work is exploratory and empirical in nature. As presented in the Materials and Methods section below, the data source is a time series of monthly values of US drug Approvals from Jan. 1939 through Dec. 2019 from the Centers of Drug Evaluation and Research (CDER) branch of the Food and Drug Administration (FDA), which "regulates over-the-counter and prescription drugs, including biological therapeutics and generic drugs<sup>1</sup>." While this is not the only institution that regulates the DDD process within the FDA, it is one that provides a publicly, reliable and valuable source of longitudinal metrics regarding the DDD process from the dawn of the review process (1939) to the present time. The methods are standard with the exception of the Chronological Hurst Exponent to explore the persistency latent in the time series. All datasets and R Project code are provided in the Electronic Supplementary Materials section for the sake of transparency and replicability as well as to encourage future researchers in investigate a potentially very interesting and informative aspect of drug development. This work then discusses the key results of both the descriptive and inferential statistics followed by a discussion on how the statistical work positively supports the hypotheses mentioned above (viz., persistency and economic cycles are latent within US drug approvals), and the ramifications of this work including potential linkages to sociological, economic, and policy features experienced over the nearly 100 years of data.

## **Materials and Methodologies**

The following summarizes the data sources and the statistical approaches used. This work is applied by nature and thus differing the mathematical formulae and technical discussion to original sources, as cited. All data and the R Project code for the statistical analysis are provided in the Electronic

<sup>&</sup>lt;sup>1</sup> <u>https://www.fda.gov/about-fda/fda-organization/center-drug-evaluation-and-research-cder</u>

Supplementary Materials section supporting this article for transparency and reproducibility, as well as for purposes of future work.

Data Sources and Data Preparation

The data was obtained from the FDA repository accessed at <a href="https://www.accessdata.fda.gov/scripts/cder/daf/">https://www.accessdata.fda.gov/scripts/cder/daf/</a> on July 16 and July 17, 2020. The data was culled from a monthly report and described as follows:

"All Approvals and Tentative Approvals by Month.

Reports include only BLAs/NDAs/ANDAs<sup>2</sup> or supplements to those applications approved by the Center for Drug Evaluation and Research (CDER) and tentative NDA/ANDA approvals in CDER. The reports do not include applications or supplements approved by the Center for Biologics Evaluation and Research (CBER).

Approvals of New Drug Applications (NDAs), Biologics License Applications (BLAs), and Abbreviated New Drug Applications (ANDAs), and supplements to those applications; and tentative approvals of ANDAs and NDAs."

Upon entry into the data-repository via the website, the number of approvals from Jan. 1939 to Dec. 2019 was then determined by month. The values were placed in Excel and then exported as a comma delimited comma-separated values (CSV) file for input into the data analysis routine.

The total dataset comprised 181,157 total approvals from Jan. 1939 until Dec 2019 (for a total of 972 monthly observations). The author notes that submission history for each approval during this roughly 100 year time-period was not found on the US FDA website.

<sup>&</sup>lt;sup>2</sup> BLAs/NDAs/ANDAs: Biologics License Applications, New Drug Applications, Abbreviated New Drug Applications

## Statistical Analysis

As mentioned above, as this is an applied paper, reference is made to the various theoretical formulae in the respective supportive citations. Many of the distribution-inquiring statistical tests selected are considered 'standard' in the sense that they are typically used in the context described and are readily available and interpretable. All methods presented below followed standard implementation; default parameters were used (as appropriate) throughout the analyses. While the R code [20] is presented in the Electronic Supplemental Materials section of this article, the steps to perform the analysis were as follows:

 Load US Approvals as a time-series and perform descriptive statistics (including autocorrelation functions) [21; R package: 'moments'].

In this step, the data is read as a time series into the R program, and descriptive statistics including moments and serial and partial correlation functions calculated.

II. Assess attributes of the time series, including:

- Normality [22; R package: 'nortest'] using the Anderson-Darling and Cramer-von Mises normality tests
- Stationarity [23; R package: 'aTSA'] using the Kwiatkowski-Phillips-Schmidt-Shin (KPSS) Unit
   Root Test for both the original and single difference
- Long-memory [24; R package: 'LongMemoryTS'] using the Qu and local Whittle score tests
- Seasonality [25; R package: 'seastests'] using the WO, QS, Friedman and Welch tests
- Nonlinearity [26; R package: 'nonlinearTseries'] using the Teraesvirta's and neural network tests, and Keenan, McLeod-Li, Tsay, and likelihood ratio tests.
- III. Determine the Chronological Hurst Exponent (that is, evaluate if the Hurst exponent over time evolves):

For a given time-series, the Hurst constant [27; R package: 'tsfeatures'] is a statistical indicator of the memory in a time-series process (or processes). In this calculation, the time-varying nature of the H constant was investigated using time windows from the first datapoint (Jan. 1939) to the end of the window length, with 1-month increments. The algorithm to calculate the Chronological Hurst Exponent is as follows:

hurstApprovals=0; end<-length(time)
for (I in 1:end) { hurstApprovals[i] <- hurst (time[1:(1+i\*1)]) }
hurstApprovals<-ts(hurstApprovals,start=c(1939,1),end=c(2019,12),frequency=12)</pre>

IV. Determine the periodicities within the time series:

Wavelet analyses used to investigate the structure of the periodicities within the time series given its dynamics (particularly its non-stationarity; see step II). Two wavelet methods were utilized: one with a smoothing (Loess) approach [28; R package: 'WaveletComp'] and one [29-31; R Package: 'dplR'] without. The average period versus the average power for each method was then calculated to elucidate the main periodicities. The dominant frequency was then re-checked with spectral analysis [32-33; R Package: 'forecast'].

## Results

#### Descriptive statistics: Elementary properties of the chromodynamics of US drug approvals

The time series of US drug approvals follows an interesting flow given the dramatic rise starting in the 1970s to 2000 then after a drastic fall with a subsequent re-rise (Figure 1).

### < Insert Figure 1 here. Figure 1: Time evolution of total US CDER Approvals >

The US drug approvals time series distribution is non-normal, platykurtic and positively skewed, with an average of 186 approvals (191 standard deviation) (Table 2 and 3). Importantly, the time series is non-

stationary, non-seasonal, and non-linear, with intrinsic persistent memory (Table 2 and figure 2), which is removed with single differencing (that is, the time series has an order of integration (number of differences to attain stationarity) of 1, I(1)). I(1) processes are rather well-represented across a spectrum of different disciplines and a broad assortment of the economic variables including US drug approvals [34].

< Insert Table 2 here: Table 2: Descriptive statistics of US approvals (rounded to tenths; units in months) >

< Insert table 3 here: Table 3: Summary of tests investigating normality, stationarity, seasonality, longmemory, and non-linearity>

< Insert Figure 2 here: Figure 2: Serial and partial correlation functions: lag is presented in months > Chronological Hurst Exponent: Existence of economic cycles and latent persistency

Using the Chronological Hurst Exponent approach to investigate the long-term memory processes of the time-series shows, interestingly, a unique trichotomized structure (Figure 3). Three periods are clearly shown: Period 1: prior to June 1947, a period of stagnation with H~0.5; Period 2: June 1947 to May 1974, a period of time-varying nature (also herein called emergent), where the H constant fluctuates rises under a degree of fluctuation; and, Period 3: May 1974 to Dec 2019, a period of saturation in which the H~1.

< Insert Figure 3 here: Figure 3: The Chronological Hurst Exponent based on US Drug Approvals (Figure 1) from 1939 to 2019>

Concordantly, the wavelet periodogram during Period 3 demonstrates that the time series contains periodicities. Several relatively long-, medium-, and short-range periodicities are observed during this period: 16-18 years (with a maximum (black ridge) occurring at 17 years), ~4-8 years, and on the

monthly, yearly, or biyearly periodicities presenting intermittently, respectively (Figure 4). The predominate periodicity is identified to be 17, 8 and 4 years from spectral analysis (Figure 5).

< Insert Figure 4 here. Figure 4: Wavelet periodogram of US approvals: black lines are the wavelet power ridges and white contour lines to border the area of wavelet power significance of 99% >

< Insert Figure 5 here. Figure 5: Wavelet period versus power with 95% significant levels in red >

### **Discussion and Conclusion**

Using time series analysis, this work finds two conceptually novel aspects of US drug approvals: the existence and evolution of persistency, and the existence of approval cycles (akin to economic cycles).

#### Persistency

Formally, persistency may be defined as the "rate at which its autocorrelation function decays to zero," or "the extent to which events today have an effect on the whole future history of a stochastic process [40]." Translating to the context of our concern, it generally means that the value of US drug approvals at a given month is closely related to its value at the prior month. The Chronological Hurst Exponent proposed herein is a simple algorithm that reiteratively calculates the Hurst exponent (a measure of persistency) over an incrementally increased time period. With each iteration, an additional data point (here the next monthly observation of US approvals) is taken into account until the exponent of the full data set is calculated. The Chronological Hurst Exponent proposed in this work elucidated a S-shaped structure reflecting a trichotomized picture of the time evolution of persistency latent within US drug approvals:

• Period 1: An 8-year (1939-1947) stagnation period in which the Hurst exponent remained at or around 0.5. An Hurst exponent at these values suggest no persistency whatsoever.

- Period 2: A 27-year (1947-1974) time-varying (emergent) period in which the Hurst exponent gradually evolved from 0.5 to 0.9. This range in the Hurst exponent suggests a growing persistency within the time series data.
- Period 3: A 45-year (1974-2019) saturation period in which the Hurst exponent remained at or around 1. A saturated Hurst exponent implies that the time series has become (for lack of a better term) inelastic; that is, any further changes in the degree and/or number of exogenous variables do not affect the persistency course of the time series (as it is already maximized).

### Cyclicity

Interpreting US drug approvals as an economic variable – a singular outcome of several complex macro-(national), meso- (cluster), and micro (firm)-inputs such as national policy and R&D spend (government, firm), potential of future rents (individual buyer, payor), science and technology innovation (tacit (e.g., staff dexterity) and explicit (e.g., patents) knowledge), and resource availability (e.g., chemicals, vials) – the existence of business cycles were investigated. Several tiered periodicities (17 years, 4-8 years, and intermittent monthly/yearly) were identified within Periods 2 and 3 of the CHE. Thus, one of the key findings of this work is that approval cycles, similar to economic cycles, exist. These approval cycles seem to be the result of explanatory variables that are working in a cumulative manner.

## Persistence and Cyclicity Interpreted

During Period 2 (27-years (1947-1974)), it is observed that 1947 was the first year in which there were one or more approvals during much of the year and had the largest number on an annual basis since the start of the collection cycle in Jan 1939. After 1947, a general rise in the number of approvals per month and per annum is observed. It is also a period of commensurate changes to the policy and social landscape pertaining to DDD, as well as continued investment into R&D. These changes were seemingly due to end of World War II (1939-1945), the beginning of the so-called 'Golden Age of Capitalism,' and

the associated economic progress [35] with a relatively small number of economic disasters (see Figure 3 in [36]). Since the 1938 Food, Drug and Cosmetic act, no significant advances in policy occurred until the 1962 Drug Amendments (see Table 1), while there were significant milestone activities in terms of congressional review (the Kefauver Hearings dealt with pricing and market control [37]. One could therefore speculate that it an overall increased economic activity (and not specific FDA policy changes, per se) that may have driven the changes in the persistency measurement.

The appearance of Period 3 (45-years (1974-2019)) suggests a uniform pressure onto the time series. Two general reasons present themselves to foment such a sustained persistent alteration in the fabric of US drug approvals: some sort of substantive and everlasting change (1) to accounting practices regarding US drug approvals (that is, how the source data was initially contrived and/or collected); or (2) in the scientific, social, economic, and/or legislative landscape. The former is unlikely to cause a persistent shift. To illustrate, FDA data sources state a change in department ownership in and around that time, as well as issues regarding changes from fiscal to calendar year practices.<sup>3</sup> It is unlikely that either of these reasons would have changed the time series in such a permanent manner. The latter reason, while likely, however, is ill-defined, but does allow for hypothesis generation.

One hypothesis that could be tested is that of a significant change in the FDA policy landscape (see Table 1) may have caused the formation of Period 3. From an FDA perspective, the 1960s and 1970s were a transformative vicennial [38]. In 1962, the Kefauver-Harris (KH) amendments to the original Food, Drug and Cosmetics Act (FD&C) of 1938 introduced (inter alia) broad requirements on drug efficacy (including key concepts of 'substantial evidence' and 'adequate and well-controlled studies'), drug quality (via good manufacturing practices), ethical guidelines (patient informed consent), and physician-researcher supervision of the clinical trials. Subsequently, a review of prior-to-1962 approved drugs were

<sup>&</sup>lt;sup>3</sup> Data record information from <u>https://www.fda.gov/about-fda/histories-product-regulation/summary-nda-approvals-receipts-1938-present</u> (extracted on July 30, 2020).

#### Persistency and cyclicity in US drug approvals

Author: Daizadeh, I.

retrospectively investigated based on the evidentiary standard of the KH amendments, which led to revocation of "over 1000 ineffective drugs and drug combinations from the marketplace (page 13 of *ibid*)." The concepts such as those introduced in the KH amendments (partly listed above) have been refined and reinforced through ongoing congressional action, directly contributing to the identified persistency affect and cyclicity. Ongoing policy actions, such as Prescription Drug User Fee Act (PDUFA) and its subsequent 5-year amendments commencing in 1992, or the introduction of new technologies may have directly contributed to innovation-based periodicities, leading to significant increases in the promulgation of guidelines that may have furthered drug approvals [34, 39].

Thinking outside of the drug development process and continuing considering the periodogram (Figure 5) and thinking of the original time series (Figure 2), the complex periodicity profile may have been motivated by socio-economic factors. Substantive economic pulses that may have affected the overall approval flow may include: Black Monday Market Crash (October 19, 1987), the Dot-Com bubble burst (Q3, 2002), and the subprime mortgage crisis (September 17, 2008), among others. Visually, the Dot-Com bubble burst seemed to coincide with a downsizing of amplitude. However, it is difficult to ascertain if the other triggers may have affected the time series.

Interestingly, if one considered the US drug approvals strictly as an economic variable, and assuming the theory of Schumpeter's economic cycles, the identified periodicities seem to coincide with certain macro-economic periodicities, with exception as no canonical long-term (> 40 years) periodicities were identified in this analysis (see Table 4). The periodicities began at different times with different durations (Figure 4). The dominant periodicity of 17, 8 and 4 years has reoccurred during the longest (45 years), medium (20 years), and short-term (intermittent) durations, respectively (Figure 5). Thus, it seems that US drug approvals follow a Juglar/Kuznets mid-term cycle with Kitchin bursts. Only time will tell if a longer-term cycle (Kondratieff) emerges, irrespective of any downside pressures (such as multi-decade bear cycles). A key difference between the identified approval cycles as compared with

Page 13 of 45

economic cycles may be the degree of importance of the regulatory context. While a potentially coarse interpretation, without the legal requirement for market approval there would not have been a US drug approvals time series, whereas for variables such as gross domestic product typically used to consider economic cycles this is not the case (as the legal regimes do not define (as much as support) the existence of these more traditional economic variables).

< Insert table 4 here. Table 4: Mapping of broad canonical economic cycles with that of periodicities associated with US Approvals >

## Further Thoughts in Light of Limitations of Current Study

There are extensions and limitations to any statistical analyses, especially when dealing with socialeconomic variables. Examples of future investigation may include:

Hypothesis:

- One could argue that the number of US drug applications may have been a more insightful variable, as applications may be either withdrawn (by the Sponsor) or rejected (by the FDA).
   Unfortunately, the author could not find this dataset.
- The number of initial US drug applications or approvals for new molecular and/or biologic entities may provide additional insight into the economics of the innovative process. In this article, the total number of US drug approvals including generics and line extensions (e.g., new indications or dosage forms) were considered, as reflected "market innovation." That is, a sponsor would not have considered seeking an approval without a market driver of some sort.

Data:

• Data integrity and completeness: This study relies on a single source dataset from the FDA. While the author feels comfortable with the data source, there is uncertainty in how the data is collected, maintained, and presented given the duration of data collection and limited-to-no ability to cross-reference.

• Data transformation: The data was transformed from irregular to a regular time-structure. That is, FDA drug approvals occurred as a function of day; these data were then aggregated into monthly values to facilitate the statistical analyses. Thus, some information may have been lost in terms of structure, as there are limited statistical routines able to manage such data.

In the author's opinion, these data are an important artifact of R&D expenditures related to the DDD industry and therefore have interesting utility. Future investigations may consider these data and analyses to support research questions such as those related to forecasting and long-memory effects of non-stationary and non-linear data. It will be interesting to revisit these analyses on a yearly basis given the recent COVID-19 crises and resultant economic challenges, with a hope that the US drug approvals remain persistent with respect to these significant triggers.

## Study Conclusions:

In conclusion, this work introduces the Chronological Hurst Exponent, an algorithm which examines the time evolution of long-term memory intrinsic to time series data. Using this algorithm, US drug approvals are examined. The CHE of US drug approvals is found to follow a distinctive S-shaped (trichotomized) curve, with three periodicities that seem to be correlative with the evolving US drug development policy landscape, as well as macro-variable changes that may be relevant to drug development. Further, using wavelet analysis, cyclicity in the frequency of US drug approvals was observed in the most recent period identified in the CHE analysis. These periodicities adds evidence to the concept of mid-term economic cycles, assuming US drug approvals data are viewed a proxy metric of innovative capacity. The empirical findings and statistical approaches outlined in this report promise an exciting new frontier of further research into the various forces driving drug development.

# Acknowledgements

The author extends gratitude N.D., S.L.D., and N.L.D. for their support of the manuscript.

## Disclosures

The author is an employee of Takeda Pharmaceuticals; however, this work was completed independently of his employment. The views expressed in this article may not represent those of Takeda Pharmaceuticals. As an Associate Editor for Therapeutic Innovation and Regulatory Science, the author was not involved in the review or decision process for this article. See Electronic Supplementary Materials for all data and methods to replicate (or extend) the results presented herein.

## **References:**

- (1) Daizadeh, I., Miller, D., Glowalla, A. et al. A general approach for determining when to patent, publish, or protect information as a trade secret. Nat Biotechnol 20, 1053–1054 (2002).
   <a href="https://doi.org/10.1038/nbt1002-1053">https://doi.org/10.1038/nbt1002-1053</a>
- (2) Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166
- (3) DiMasi, J.A.; Grabowski, H.G. (2012) Chapter 2: R&D costs and returns to new drug development: a review of the evidence. In The Oxford Handbook of the Economics of the Biopharmaceutical Industry (edited by Patricia M. Danzon, Sean Nicholson). Oxford University Press.
- (4) Munos, B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov 8, 959–968
   (2009). <u>https://doi.org/10.1038/nrd2961</u>
- (5) Parida, D., Mehdiratta, R. & Saberwal, G. How many patents does a biopharmaceutical company need?. Nat Biotechnol 26, 763–766 (2008). <u>https://doi.org/10.1038/nbt0708-763</u>
- (6) Agarwal, P., Searls, D. Can literature analysis identify innovation drivers in drug discovery?. Nat Rev Drug Discov 8, 865–878 (2009). <u>https://doi.org/10.1038/nrd2973</u>
- (7) D'Alise, C.; Giustiniano, L.; Peruffo E. (2014) Innovating through Clusters. International Journal of Engineering Business Management. <u>https://doi.org/10.5772/59028</u>
- (8) Daizadeh, I. (2009) An intellectual property-based corporate strategy: An R&D spend, patent, trademark, media communication, and market price innovation agenda. Scientometrics 80, 731–746. <a href="https://doi.org/10.1007/s11192-008-2105-9">https://doi.org/10.1007/s11192-008-2105-9</a>
- (9) Daizadeh, I. Issued US patents, patent-related global academic and media publications, and the US market indices are inter-correlated, with varying growth patterns. Scientometrics 73, 29–36 (2007). <u>https://doi.org/10.1007/s11192-007-1749-1</u>

(10)Kozlowski, D. (2019). Old series, new signals: The economic cycle in light of wavelet analysis.

Cuadernos Del CIMBAGE, 2(21). Obtained from:

https://ojs.econ.uba.ar/index.php/CIMBAGE/article/view/1587

(11)Besomi, D. (2005) Clément Juglar and the transition from crises to business cycle theories. Paper prepared for a conference on the occasion of the centenary of the death of Clément Juglar, Paris, 2 December 2005. Obtained from:

https://www.unil.ch/files/live/sites/cwp/files/users/neyguesi/public/D. Besomi\_

http://citeseerx.ist.psu.edu/viewdoc/download?doi=10.1.1.693.7740&rep=rep1&type=pdf

(12)Kitchin, J. (1932) Cycles and Trends in Economic Factors. The Review of Economics and Statistics.

5(1): 10-16. <u>https://www.jstor.org/stable/pdf/1927031.pdf</u>

- (13)Kondratieff, N.D.; Stolper, W.F. (1935) The long waves of economic life. The Review of Economics and Statistics 17(6): 105-115. <u>https://www.cannonfinancial.com/uploads/main/Long-Waves-in-</u> <u>Economic-Life.pdf</u>
- (14)Kwasnicki, W. (Date Unknown) Kitchin, Juglar and Kuznetz business cycles revisited. Obtained on 08-June-2020 from <u>http://kwasnicki.prawo.uni.wroc.pl/todownload/Kwasnicki\_cyclesJEBO.pdf</u>
- (15)Alvarez-Ramirez, J; Rodriguez,E; Ibarra-Valdez, C (2020) Medium-term cycles in the dynamics of the Dow Jones Index for the period 1985-2019. Physica A 546 124017 https://doi.org/10.1016/j.physa.2019.124017
- (16)Saha, K; Madhavan; V; Chandrashekhar, G (2020). Pitfalls in long memory research. Cogent Economics and Finance, 8(1), 1733280. <u>https://doi.org/10.1080/23322039.2020.1733280</u>
- (17) Chamoli, A; Bansal, AR; Dimri,VP (2007) Wavelet and rescaled range approach for the Hurst coefficient for short and long time series. Computers & Geosciences 33(1) 83-93 <u>https://doi.org/10.1016/j.cageo.2006.05.008</u>

(18) Mandelbrot, BB; Wallis, JR (1968) Noah, Joseph, and Operational Hydrology, Water Resour. Res.,

4(5), 909-918, doi:10.1029/WR004i005p00909

(19) Walnut, DF (2013) An Introduction to Wavelet Analysis. Germany: Birkhäuser Boston.

- (20)R Core Team (2020) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. <u>https://www.R-project.org/</u>.
- (21)Komsta, L; Novomestky, F (2015) moments: Moments, cumulants, skewness, kurtosis and related tests. R package version 0.14 <u>https://CRAN.R-project.org/package=moments</u>
- (22)Gross, J; Ligges, U (2015) nortest: Tests for Normality. R package version 1.0-4. <u>https://CRAN.R-project.org/package=nortest</u>
- (23)Qiu,D (2015). aTSA: Alternative Time Series Analysis. R package version 3.1.2. <u>https://CRAN.R-project.org/package=aTSA</u>
- (24)Leschinski,C (2019). LongMemoryTS: Long Memory Time Series. R package version 0.1.0. https://CRAN.R-project.org/package=LongMemoryTS
- (25)Ollech,D (2019). seastests: Seasonality Tests. R package version 0.14.2. https://CRAN.R-

project.org/package=seastests

- (26)Garcia,C.A. (2020). nonlinearTseries: Nonlinear Time Series Analysis. R package version 0.2.10. https://CRAN.R-project.org/package=nonlinearTseries
- (27)Hyndman, R; Kang, Y; Montero-Manso, P; Talagala,T; Wang, E.; Yang, Y; O'Hara-Wild,M (2020). tsfeatures: Time Series Feature Extraction. R package version 1.0.2. <u>https://CRAN.R-</u>

project.org/package=tsfeatures

- (28)Roesch,A.; Schmidbauer,H (2018). WaveletComp: Computational Wavelet Analysis. R package version 1.1. <u>https://CRAN.R-project.org/package=WaveletComp</u>
- (29)Bunn, AG (2008). A dendrochronology program library in R (dplR). Dendrochronologia, 26 (2), 115 124. ISSN 1125-7865, <u>https://doi.org/10.1016/j.dendro.2008.01.002</u>

- (30)Bunn, AG (2010). Statistical and visual cross-dating in R using the dplR library. Dendrochronologia, 28(4), 251-258. ISSN 1125-7865, <u>https://doi.org/10.1016/j.dendro.2009.12.001</u>
- (31)Bunn, A; Korpela, M; Biondi, F; Campelo, F; Mérian, P; Qeadan, F; Zang, C (2020). dplR: Dendrochronology Program Library in R. R package version: 1.7.1. <u>https://CRAN.R-project.org/package=dplR</u>
- (32)Hyndman, R; Athanasopoulos, G; Bergmeir, C; Caceres, G; Chhay, L; O'Hara-Wild, M; Petropoulos, F;
   Razbash, S; Wang, E; Yasmeen, F (2020). forecast: Forecasting functions for time series and linear
   models\_. R package version 8.12, <a href="http://pkg.robjhyndman.com/forecast">http://pkg.robjhyndman.com/forecast</a>
- (33)Hyndman, RJ; Khandakar, Y (2008). "Automatic time series forecasting: the forecast package for R." Journal of Statistical Software, 26(3), 1-22. <u>http://www.jstatsoft.org/article/view/v027i03</u>
- (34)Daizadeh I. Investigating Rates of Food and Drug Administration Approvals and Guidances in Drug Development: A Structural Breakpoint/Cointegration Timeseries Analysis. Ther Innov Regul Sci. 54(5):1056-1067. doi: 10.1007/s43441-020-00123-5. Epub 2020 Jan 31. PMID: 32006390.
- (35)Zakamulin, V; Hunnes, JA (2020) Stock earnings and bond yields in the US 1871–2017: The story of a changing relationship, The Quarterly Review of Economics and Finance,

https://doi.org/10.1016/j.qref.2020.05.013

- (36)Coric, B (2020) Economic disasters: A new data set. Finance Research Letters 101612 https://doi.org/10.1016/j.frl.2020.101612
- (37)Greene, JA; Podolsky, SH (2012) Reform, regulation, and pharmaceuticals-The The Kefauver–Harris Amendments at 50. N. Engl. J. Med. 367:1481-1483 DOI: 10.1056/NEJMp1210007
- (38)Junod, S. W. (2020;2008) FDA and Clinical Drug Trials: A Short History, in A Quick Guide to Clinical Trials, Madhu Davies and Faiz Kerimani, eds. (Washington: Bioplan, Inc.: 2008), pp. 25-55; viewed on July 30 from the FDA website: <u>https://www.fda.gov/media/110437/download</u>

- (39)Daizadeh, I. (2020) Since the Mid-2010s FDA Drug and Biologic Guidelines have been Growing at a Faster Clip than Prior Years: Is it Time to Analyze Their Effectiveness? Ther Innov Regul Sci. https://doi.org/10.1007/s43441-020-00233-0
- (40)Caporale, Guglielmo Maria and Pittis, Nikitas, Persistence in Macroeconomic Time Series: Is it a Model Invariant Property?. Revista de Economia del Rosario, Vol. 4, No. 2, pp. 117-142, 2001, Available at SSRN: <u>https://ssrn.com/abstract=928506</u>
- (41)Chorniy, A., Bailey, J., Civan, A. and Maloney, M. (2021), Regulatory review time and pharmaceutical research and development. Health Economics, 30: 113-128. <u>https://doi.org/10.1002/hec.4180</u>
- (42)DiMasi, J.A., Wilkinson, M. The Financial Benefits of Faster Development Times: Integrated Formulation Development, Real-Time Manufacturing, and Clinical Testing. *Ther Innov Regul Sci* **54**, 1453–1460 (2020). <u>https://doi.org/10.1007/s43441-020-00172-w</u>

Year	US Drug Regulation
1938	Act and Requirements for Premarket Drug Safety
	and New Labeling
1941	The Insulin Amendment
1945	The Penicillin Amendment
1951	Durham-Humphrey Amendment
1962	Kefauver-Harris Drug Amendments
1977	Introduction of the Bioresearch Monitoring
	Program
1981	Revision of the regulations for human subject
	protections
1982	Tamper-resistant Packaging Regulations issued
1983	Orphan Drug Act
1984	Drug Price Competition and Patent Term
	Restoration Act (Hatch–Waxman Act)
1987	Investigational drug regulations
1988	FDA Act of 1988 and Prescription Drug Marketing
	Act
1989	Guidelines on significant use in elderly people
1991	Accelerated review of drugs for life-threatening
	diseases; Common Rule adopted across agencies
1992	Generic Drug Enforcement Act; co-establishes
	International Conference on Harmonization (ICH);
	Prescription Drug User Fee Act (PDUFA I)
1993	MedWatch launched; revising women of
	childbearing potential in early phase drug studies
	policies and assessments of genders-specific
4004	medication responses
1994	Uruguay Round Agreements Act
1995	Cigarettes as 'drug delivery devices'
1997	FDA Modernization Act (FDAMA); reauthorization
4000	of PDUFA II
1998	Adverse Event Reporting System (AERS);
4000	Demographic Rule; Pediatric Rule
1999	ClinicalTrials.gov; guidances for electronic
	submissions; drug facts; Prescription Drug
	Broadcasting Advertising Final Guidance;
	Managing the Risks from Medical Product use:
2000	Risk Management Framework published
	Data Quality Act
2002	Best Pharmaceuticals for Children Act; Public
	Health Security and Bioterrorism Preparedness

Table 1: Brief Milestones in FDA Drug Regulation [Daizadeh, 202	<b>0]</b> <sup>4</sup> .
---	--------------------------

<sup>&</sup>lt;sup>4</sup> <u>https://www.fda.gov/about-fda/virtual-exhibits-fda-history/brief-history-center-drug-evaluation-and-research</u>

	and Response Act of 2002; Current good
	manufacturing practice (cGMP) initiative; PDUFA
	III; outcomes of pregnancies registries guidance
2003	Medicare Prescription Drug Improvement and
	Modernization Act; Pediatric Research Equity Act
2004	Project BioShield Act of 2004; Anabolic Steroid
	Control Act of 2004; "Innovation or Stagnation?—
	Challenge and Opportunity on the Critical Path to
	New Medical Products" published; bar code
	introduced
2005	Drug Safety Board announced; risk management
	performance goal guidances
2006	Requirements on Content and Format of Labeling
	for Human Prescription Drug and Biological
	Products final rule
2007	PDUFA IV; FDA Amendments Act (FDAAA)
2008	Sentinel Initiative
2009	FDA Transparency Initiative
2010	FDA Transparency Results Accountability
	Credibility Knowledge Sharing (TRACK)
2012	PDUFA V; Launch of FDA Adverse Event Reporting
	System (FAERS); Food and Drug Administration
	Safety and Innovation Act (FDASIA); Generic Drug
	User Fee Amendment
2013	Drug Quality and Security Act; Mobile Medical
	Applications; Global Unique Device Identification
	Database (GUDID)
2016	21st Century Cures Act
2017	Current Good Manufacturing Practice (cGMP)
	Requirements for Combination Products; FDA
	Reauthorization Act (FDARA; PDUFA VI)

Minimum	1 <sup>st</sup> Quartile	Median	Mean	Standard Deviation	3 <sup>rd</sup> Quartile	Maximum	Kurtosis	Skew
0	5.0	164	186.4	190.9	392.2	858	2.6	0.7

# Table 2: Descriptive statistics of US approvals (rounded to tenths; units in months)

# Table 3: Summary of tests investigating normality, stationarity, seasonality, long-memory, and nonlinearity

Test Category	Test Name	Test statistic	Outcome against null hypothesis
Normality	Anderson-Darling test	p-value < 2.2e^16	Normal distribution
	Cramer-von Mises test	p-value < 7.37e-10	rejected
Stationarity	KPSS unit root test*	0.01 (for no drift/no trend; for drift/no	Stationarity rejected
		trend; for drift/trend)	
Long memory	Qu test*	1.033545 versus 1.517	Long memory accepted
- 0 ,		(alpha=0.01;eps=0.02)	
	Multivariate local	1.668473 versus 1.517	-
	Whittle Score*	(alpha=0.01)	
Seasonality	Webel-Ollech test	p-value 0.05	"The WO-test does not
			identify seasonality"
	QS test, Friedman,		False – seasonality
	Welch tests		rejected
Linearity	Teraesvirta's neural	p-value=0	Linearity in "mean"
	network test		rejected
	White neural network	p-value=0	Linearity in "mean"
	test		rejected
	Keenan's one-degree	p-value=3.889e^-5	The time series follows
	test		some AR process
			rejected
	McLeod-Li test	p-value=0	The time series follows
			some ARIMA process
			rejected
	Tsay's test	p-value=6.45e^-14	Time-series follows
			some AR process
			rejected
	Likelihood ratio test for	p-value=0.0004552571	Time-series follows
	threshold non-linearity		some TAR process
			rejected
•	e stationary data. As such, as tl		
series from the origi	inal time-series was 1, the diffe	rence was used in the spec	cific test demarcated.

# Table 4: Mapping of broad canonical economic cycles with that of periodicities associated with US Approvals

Theory	Periodicity	US Approvals
Kitchin Short-Term Cycle Cycle	3.5 years	Months to biannual
Juglar Mid-Term Cycle	7-11 years	4-8 years
Kuznets Medium-Term Cycle	15-25 years	17 years
Kondratieff Long-Term Cycle	40-60 years	





Figure 1: The number of monthly US CDER Approvals as a function of year from 1939 to 2019










Figure 3: The Chronological Hurst Exponent based on US Drug Approvals (Figure 1) from 1939 to 2019

# Figure 4: Wavelet periodogram of US approvals: black lines are the wavelet power ridges and white contour lines to border the area of wavelet power significance of 99%



wavelet power spectrum





## **Supplementary Materials**

## I. Data Collection

The FDA website <u>https://www.accessdata.fda.gov/scripts/cder/daf/</u> was access on July 16 and July 17, 2020. The data was culled from a monthly report and described as follows (see Figure 1):


"All Approvals and Tentative Approvals by Month.

Reports include only BLAs/NDAs/ANDAs or supplements to those applications approved by the Center for Drug Evaluation and Research (CDER) and tentative NDA/ANDA approvals in CDER. The reports do not include applications or supplements approved by the Center for Biologics Evaluation and Research (CBER).

Approvals of New Drug Applications (NDAs), Biologics License Applications (BLAs), and Abbreviated New Drug Applications (ANDAs), and supplements to those applications; and tentative approvals of ANDAs and NDAs."

Upon entry into the data-repository via the website, the number of approvals from Jan. 1939 to Dec. 2019 was then determined by month (see Figure 2). The values were placed in Excel and then exported as a comma delimited CSV file for input into the data analysis routine.

Figure 1: The FDA web data-repository allowing search of drug approval reports as a function of month.



Home > Drug Database	rs > DragateFDA					
	18 B.					
)rugs@F	DA: FDA-Approved Drug	gs				
SHARE STWEET	in LIKKEDIK 🧐 PIKIT 🖾 EWAIL 🔒 PRINT					
ome   Previous Pa	age					
		All Appro	ovals and Tentative February 1939	Approvals		
	approvals of NDAs, BLAs, ANDAs, and approved su	pplements to those app	lications, and tentative Al	IDA/NDA approvals during th	e selected month. This report does	not include BLAs/NDAs and
	e applications approved by CBER.					
	- and the second state of					
lick on the Drug Na	me and Application Number to see information ab	out the drug (for examp	le, regulatory history, labe	ling, reviews by FDA staff).		
lick on the Drug Na	- and the second state of	ana 100 <b>100 100</b>		ling, reviews by FDA staff).		
lick on the Drug Na	me and Application Number to see information ab	out the drug (for examp Month: Febr		ling, reviews by FDA staff).		
lick on the Drug Na	ime and Application Number to see information ab duced on July 26, 2020.	Month: Febr		Search		
lick on the Drug Na his report was proc CSV Excel F	me and Application Number to see information ab duced on July 26, 2020.	Month: Febr	uany 🧹 Year: 1939 revious Month Next M	Search		
lick on the Drug Na his report was proc CSV Excel F Approval Date	me and Application Number to see information ab duced on July 26, 2020. Yirit * Drug Neme	Month: Febr < P Submission	uary Vear: 1939 revious Month Next M Active Ingredients	Search onth≥ ♦ Company (	Submission Classification	\$ubmission Status
lick on the Drug Na his report was proc CSV Excel F Approval Date	me and Application Number to see information ab duced on July 26, 2020.	Month: Febr	uany 🧹 Year: 1939 revious Month Next M	Search	Submission Classification	Submission Status     Approval
lick on the Drug Na lis report was proc CSV Excel F Approval Date 02/09/1939	me and Application Number to see information ab duced on July 26, 2020. Print * Drug Nisme HEPARIN SODIUM	Month: Febr < P Submission	uary Vear: 1939 revious Month Next M Active Ingredients	Search onth≥ ♦ Company (	Submission Classification	
lick on the Drug Na Nis report was proc CSV Excel F Approval Date 02/09/1030	me and Application Number to see information ab duced on July 26, 2020.	Month: Febr	uany Vear: 1939 revious Month Next M Axtive Ingredients HEPARIN SODIUM	✓ Search onth≥ ♦ Company ( ORGANON USA INC	Submission Classification	Approval
lick on the Drug Na his report was proc CSV Excel F	me and Application Number to see information ab duced on July 26, 2020.           "Orug Neme           HEPARIN SOUUM NDA ROUSS2           DUURAMN LOCK FLUSH NDA ROUSS2           UDURAMN SOUUM	Month: Febr <p Submission ORIG-1 ORIG-1</p 	vany Vear: 1939 revious Month Next M Active Ingredients HEPARIN SODIUM	Search Search Company Geodesine ORGANON USA INC ORGANON USA INC	Submission Classification	Approval Approval

# II. Statistical Analysis

Install R from: <u>https://cloud.r-project.org/</u>
citation()

R Core Team (2020). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. URL <u>https://www.R-project.org/</u>.

version

platform	x86_64-w64-mingw32
arch	x86_64
OS	mingw32
system	x86_64, mingw32
status	
major	4
minor	0.2
year	2020
month	06
day	22
svn rev	78730
language	R
version.string	R version 4.0.2 (2020-06-22)
nickname	Taking Off Again

**#Step 1: Load data, convert to time series, perform descriptive statistics, and autocorrelation** Input <- read.csv(file="c:\\Users/pzn6811/OneDrive - Takeda/Desktop/GLOC/read.csv", header=T, sep=",")


Input<-na.omit(Input) #excel seems to have some NAs at the end of column

time<-ts(Input\$Number.of.Approvals,start=c(1939,1),end=c(2019,12),frequency=12)

time

Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

1040													
1940	0	0	0	2	0	0	0	0	1	0	0	0	
1941	1	0	0	0	0	1	1	3	0	0	0	0	
1942	0	1	0	0	1	0	0	0	0	0	2	1	
1943	0	0	1	0	3	1	0	0	0	0	0	1	
1944	0	0	0	1	1	0	1	0	0	0	0	1	
1945	0	1	0	0	0	0	0	0	1	1	0	0	
1946	3	1	1	1	1	0	0	2	0	1	1	0	
1947	2	1	1	1	0	2	3	2	0	1	0	1	
1948	0	3	2	2	0	0	2	0	1	1	6	0	
1949	0	0	1	1	2	1	2	1	1	2	0	1	
1950	1	0	2	4	1	5	4	1	2	0	2	1	
1951	1	0	2	2	4	4	2	1	1	0	2	2	
1952	5	1	2	2	0	2	0	4	2	0	2	4	
1953	8	3	2	7	5	1	7	0	7	1	6	9	
1954	4	0	5	12	1	5	3	1	11	. 2	2 9	94	
1955	3	3	6	6	8	4	8	13	5	2	4	3	
1956	0	1	6	2	4	1	4	3	2	7	3	1	
1957	2	5	2	13	8	4	3	3	4	5	6	5	
1958	6	2	2	4	2	5	4	4	6	5	0	4	
1959	3	6	3	5	8	4	4	8	7	3	6	5	
1960	14	4	5	5	5	8	2	1	5	8	8	8	
1961	4	2	25	13	1	1	8	61	.3	6	10	1	5
1962	4	7	11	5	7	7	6	6	7	4	3	10	



summary(time)

Min. 1st Qu. Median Mean 3rd Qu. Max. 0.0 5.0 164.0 186.4 329.2 858.0

library(moments)
citation("moments")

Lukasz Komsta and Frederick Novomestky (2015). moments: Moments, cumulants, skewness, kurtosis and related tests. R package version 0.14. https://CRAN.R-project.org/package=moments

sd(time)

190.9333

Kurtosis(time) #platykurtic (excess kurtosis = kurtosis - 3)

2.598539


Skewness(time)

0.6980762


acf(time);pacf(time)

ndiffs(time)

[1] 1







#Step 2: Perform normality, stationarity, seasonality, long-memory, and non-linearity tests

#normality test

library(nortest) #all normality tests rejected hypothesis of normality – presenting two citation("nortest")

Juergen Gross and Uwe Ligges (2015). nortest: Tests for Normality. R package version 1.0-4. https://CRAN.R-project.org/package=nortest

ad.test(time) #null normality

Anderson-Darling normality test data: time A = 48.166, p-value < 2.2e-16

Cvm.test(time)

```
Cramer-von Mises normality test
data: time
W = 7.5428, p-value = 7.37e-10
Warning message:
In cvm.test(time) :
p-value is smaller than 7.37e-10, cannot be computed more accurately
```

#stationarity test

```
Library(aTSA)
```

Citation("aTSA")

```
Debin Qiu (2015). aTSA: Alternative Time Series Analysis. R package version 3.1.2. https://CRAN.R-project.org/package=aTSA
```

```
stationary.test(time,method="kpss")
```

```
KPSS Unit Root Test
       alternative: nonstationary
       Type 1: no drift no trend
       lag stat p.value
       76.32 0.01
        _____
       Type 2: with drift no trend
       lag stat p.value
       7 7 0.01
       -----
       Type 1: with drift and trend
       lag stat p.value
       7 0.671 0.01
        _____
       Note: p.value = 0.01 means p.value <= 0.01
       : p.value = 0.10 means p.value >= 0.10
stationary.test(diff(time),method="kpss")
```

KPSS Unit Root Test alternative: nonstationary

Type 1: no drift no trend lag stat p.value 7 0.0776 0.1 -----Type 2: with drift no trend lag stat p.value 7 0.0281 0.1 -----Type 1: with drift and trend lag stat p.value 7 0.0162 0.1 -----Note: p.value = 0.01 means p.value <= 0.01 : p.value = 0.10 means p.value >= 0.10

```
#long-memory test
```

```
library(LongMemoryTS)
```

```
citation("LongMemoryTS")
```

Christian Leschinski (2019). LongMemoryTS: Long Memory Time Series. R package version 0.1.0. https://CRAN.R-project.org/package=LongMemoryTS

```
m<-floor(1+500^0.75)
```

# Qu test

Qu.test(diff(Input\$Number.of.Approvals),m) \$W.stat [1] 1.033545

\$CriticalValues

```
eps=.02 eps=.05
alpha=.1 1.118 1.022
alpha=.05 1.252 1.155
alpha=.025 1.374 1.277
alpha=.01 1.517 1.426
```

#Multivariate local Whittle Score

MLWS(diff(Input\$Number.of.Approvals), m=m)

\$B [,1] [1,] 1 \$d [1] 0.9172231

ŚW.stat [1] 0.9172231 **\$CriticalValues** alpha=.1 alpha=.05 alpha=.025 alpha=.01 1.252 1.374 1.517 1.11`8 #Seasonality tests library(seastests) citation("seastests") Daniel Ollech (2019). seastests: Seasonality Tests. R package version 0.14.2. https://CRAN.R-project.org/package=seastests #Webel-Ollech overall seasonality test summary(wo(time)) Test used: WO Test statistic: 0 P-value: 110.05105411 The WO - test does not identify seasonality #calculate through variety of tests isSeasonal(time, "qs") #QS test [1] FALSE isSeasonal(time, "fried") #Friedman test [1] FALSE isSeasonal (time, "welch") #Welch test [1] FALSE **#Nonlinearity tests** library(nonlinearTseries) citation("nonlinearTseries") Constantino A. Garcia (2020). nonlinearTseries: Nonlinear Time Series Analysis. R package version 0.2.10. https://CRAN.R-project.org/package=nonlinearTseries > nonlinearityTest(time) \*\* Teraesvirta's neural network test \*\* Null hypothesis: Linearity in "mean" X-squared = 227.9227 df = 2 p-value = 0

\*\* White neural network test \*\* Null hypothesis: Linearity in "mean" X-squared = 227.1936 df = 2 p-value = 0

\*\* Keenan's one-degree test for nonlinearity \*\*Null hypothesis: The time series follows some AR processF-stat = 17.08669 p-value = 3.888728e-05

\*\* McLeod-Li test \*\* Null hypothesis: The time series follows some ARIMA process Maximum p-value = 0

```
** Tsay's Test for nonlinearity **Null hypothesis: The time series follows some AR processF-stat = 2.733688 p-value = 6.342547e-14
```

\*\* Likelihood ratio test for threshold nonlinearity \*\* Null hypothesis: The time series follows some AR process

Alternative hypothesis: The time series follows some TAR process X-squared = 47.58834 p-value = 0.0004552571

## #Step 3: Develop Hurst over time

library(tsfeatures) citation("tsfeatures")

Rob Hyndman, Yanfei Kang, Pablo Montero-Manso, Thiyanga Talagala, Earo Wang, Yangzhuoran Yang and Mitchell O'Hara-Wild (2020). tsfeatures: Time Series Feature Extraction. R package version 1.0.2. https://CRAN.R-project.org/package=tsfeatures


hurstApprovals=0

end<-length(time)

for (i in 1:end) { hurstApprovals[i] <- hurst (time[1:(1+i\*1)]) }

hurstApprovals<-ts(hurstApprovals,start=c(1939,1),end=c(2019,12),frequency=12)</pre>

plot(hurstApprovals)



## **#Identify periods**

## **#Method 1: The Wavelet Power Spectrum Of A Single Time Series** #Note: Loess smoothing as default is 0.75 for this parameter


library(WaveletComp)

citation("WaveletComp")


Angi Roesch and Harald Schmidbauer (2018). WaveletComp: Computational Wavelet Analysis. R package version 1.1. https://CRAN.R-project.org/package=WaveletComp

```
monthyear <- seq(as.Date("1939-01-01"), as.Date("2019-12-31"), by = "month")
monthyear <- strftime(monthyear, format = "%b %Y")
c<- analyze.wavelet(data.frame(time),"time", dt=1/12, dj=0.1)
wt.image(c, main = "wavelet power spectrum", periodlab = "Period (Years)", timelab = "Month /Year",
spec.time.axis = list(at = 1:length(monthyear), labels = monthyear))</pre>
```

#### wavelet power spectrum



wt.avg(c)



# #Method 2: Continuous Morlet Wavelet Transform

Library(dplR);citation("dplR")

Bunn AG (2008). "A dendrochronology program library in R (dplR)."\_Dendrochronologia\_, \*26\*(2), 115-124. ISSN 1125-7865, doi:10.1016/j.dendro.2008.01.002 (URL: https://doi.org/10.1016/j.dendro.2008.01.002).


Bunn AG (2010). "Statistical and visual crossdating in R using the dplR library." \_Dendrochronologia\_, \*28\*(4), 251-258. ISSN 1125-7865, doi: 10.1016/j.dendro.2009.12.001 (https://doi.org/10.1016/j.dendro.2009.12.001).

Andy Bunn, Mikko Korpela, Franco Biondi, Filipe Campelo, Pierre Mérian, Fares Qeadan and Christian Zang (2020). dplR: Dendrochronology Program Library in R. R package version 1.7.1. https://CRAN.R-project.org/package=dplR


wave.out <- morlet(time, p2 = 8, dj = 0.1, siglvl = 0.95)

# wave.out\$period <- wave.out\$period/12

# wavelet.plot(wave.out)



wave.avg <- data.frame(power = apply(wave.out\$Power, 2, mean), period = (wave.out\$period))
plot(wave.avg\$period, wave.avg\$power, type = "l")</pre>



# **#Confirm time series frequency**

library(forecast);citation("forecast")

Hyndman R, Athanasopoulos G, Bergmeir C, Caceres G, Chhay L, O'Hara-Wild M, Petropoulos F, Razbash S, Wang E, Yasmeen F (2020). forecast: Forecasting functions for time series and linear models\_. R package version 8.12, <URL: http://pkg.robjhyndman.com/forecast>.

Hyndman RJ, Khandakar Y (2008). "Automatic time series forecasting: the forecast package for R." \_Journal of Statistical Software\_, \*26\*(3), 1-22. <URL: http://www.jstatsoft.org/article/view/v027i03>.

findfrequency(time) # dominant frequency is determined from a spectral analysis of the time series

[1] 17